1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 63629-1198
  5. Product Images: Simvastatin

Product Images Simvastatin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 12 images provide visual information about the product associated with Simvastatin NDC 63629-1198 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Footnote for Table 3 - Footnote for Table 3

Footnote for Table 3 - Footnote for Table 3

This text describes the results of a chemical assay showing information about potential inhibitors of CYP3Ad such as ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone. It also includes details about the effects of grapefruit juice on simvastatin pharmacokinetics. The text mentions two studies, one with grapefruit juice administered three times per day for two days and another where grapefruit juice was administered with breakfast for three days. Simvastatin was administered on the third day.*

Label - lbl636291198

Label - lbl636291198

This is a description of Simvastatin tablets, a prescription medication used to lower cholesterol in adults. The tablets contain 20 mg of Simvastatin, which needs to be kept out of the reach of children and stored between 20 to 25°C. They should be dispensed in a tightly sealed and light-resistant container with a child-resistant closure. The code "NDC 63629-1198-1" refers to the registration code of the drug.*

Figure 9 - simvastatin 10

Figure 9 - simvastatin 10

table2 - simvastatin 2

table2 - simvastatin 2

The table shows adverse reactions reported by patients treated with Simvastatin compared to Placebo. The reactions are categorized by body system, and only those with a frequency greater than or equal to 2% are displayed. Simvastatin was associated with a higher incidence of edema, abdominal pain, atrial fibrillation, constipation, gastritis, diabetes mellitus, myalgia, headache, insomnia, vertigo, bronchitis, sinusitis, and eczema. The frequency of urinary tract infections was similar between the two groups.*

Structure - simvastatin 3

Structure - simvastatin 3

table 3 - simvastatin 4

table 3 - simvastatin 4

table 4 - simvastatin 5

table 4 - simvastatin 5

Figure 5 - simvastatin 6

Figure 5 - simvastatin 6

This appears to be a data table with information regarding major vascular events and major coronary events in patients taking Simvastatin versus those taking a placebo. The table lists the number of patients in each group with or without coronary or peripheral vascular disease and various risk ratios. Therefore, this description provides information on the dataset but may not be helpful for the general audience.*

Figure 6 - simvastatin 7

Figure 6 - simvastatin 7

Figure 7 - simvastatin 8

Figure 7 - simvastatin 8

Figure 8 - simvastatin 9

Figure 8 - simvastatin 9

table 1 - table1

table 1 - table1

This is a table listing drug interactions that are associated with increased risk of myopathy and rhabdomyolysis. It provides prescribing recommendations for interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, verapamil, diltiazem, amiodarone, and lomitapide among others. For Chinese patients, Niacin is not recommended with simvastatin. Patients with HoFH should not exceed 20 Lomitapide. Daptomycin should be temporarily suspended when taking simvastatin, and grapefruit juice should be avoided. The last text seems to be a typo and does not provide any useful information.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.